Current status of antibody therapy for breast cancer

被引：15
|
作者：
Masakazu Toi
Masahiro Takada
Hiroko Bando
Kazumi Toyama
Hiroyasu Yamashiro
Shinichiro Horiguchi
Shigehira Saji
机构：
[1] Tokyo Metropolitan Komagome Hospital,Department of Surgery
[2] Tokyo Metropolitan Cancer and Infectious Disease Center,Department of Pathology
[3] Komagome Hospital,undefined
来源：
Breast Cancer | 2004年 / 11卷 / 1期
关键词：
Her-2; Antibody; Trastuzumab; Breast cancer;
D O I：
10.1007/BF02967994
中图分类号：
学科分类号：
摘要：
Antibody therapy with trastuzumab has greatly impacted breast cancer treatment. Combination treatment with trastuzumab is regarded currently as a first-line therapy for metastatic breast cancers that overexpress Her-2. It has become routine practice to examine the status of Her-2 expression in primary tumors. The impact of this therapy might be as great as that of endocrine therapy from a historical point of view. A number of new approaches using trastuzumab for seeking individualized treatment are being tested in current clinical trials. We reviewed recent advances in trastuzumab treatment and discuss the future of antibody therapy for breast cancer.
引用
收藏
页码：10 / 14
页数：4
相关论文
共 50 条
  • [1] Current status of hormone therapy and breast cancer
    Norman, RJ
    MacLennan, AH
    HUMAN REPRODUCTION UPDATE, 2005, 11 (06) : 541 - 543
  • [2] Current status of adjuvant therapy of breast cancer
    Browne, V
    Buzdar, AU
    Hortobagyi, GN
    CANCER JOURNAL - FRANCE, 1996, 9 (04): : 174 - 176
  • [3] Current status of endocrine therapy for breast cancer
    Yasuo Miyoshi
    Tetsuya Taguchi
    Yasuhiro Tamaki
    Shinzaburo Noguchi
    Breast Cancer, 2003, 10 (2) : 105 - 111
  • [4] Current status of cancer therapy with radiolabeled monoclonal antibody
    Oriuchi, N
    Higuchi, T
    Hanaoka, H
    Iida, Y
    Endo, K
    ANNALS OF NUCLEAR MEDICINE, 2005, 19 (05) : 355 - 365
  • [5] Current status of cancer therapy with radiolabeled monoclonal antibody
    Noboru Oriuchi
    Tetsuya Higuchi
    Hirofumi Hanaoka
    Yasuhiko Iida
    Keigo Endo
    Annals of Nuclear Medicine, 2005, 19 : 355 - 365
  • [6] Monoclonal antibody-based targeted therapy in breast cancer: Current status and future directions
    Bernard-Marty, Chantal
    Lebrun, Fabienne
    Awada, Ahmad
    Piccart, Martine J.
    DRUGS, 2006, 66 (12) : 1577 - 1591
  • [7] Current status of adjuvant endocrine therapy for breast cancer
    Ingle, JN
    CLINICAL CANCER RESEARCH, 2001, 7 (12) : 4392S - 4396S
  • [8] Current status of therapy for breast cancer worldwide and in Japan
    Park, Youngjin
    Kitahara, Tomoaki
    Takagi, Ryuichi
    Kato, Ryoji
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2011, 2 (02): : 125 - 134
  • [9] Current status of endocrine therapy for advanced breast cancer
    Bland, KI
    ANNALS OF SURGICAL ONCOLOGY, 1999, 6 (08) : 4S - 7S
  • [10] High dose therapy of breast cancer: current status
    Dawson, LK
    Leonard, RCF
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 1999, 30 (01) : 35 - 43
12345